Herpes simplex glycoprotein vaccine - Takeda

Drug Profile

Herpes simplex glycoprotein vaccine - Takeda

Latest Information Update: 16 Oct 2000

Price : $50

At a glance

  • Originator Takeda
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 16 Oct 2000 Discontinued-Preclinical for Herpes simplex virus infections in Japan (Unknown route)
  • 13 Jun 2000 No-Development-Reported for Herpes simplex virus infections in Japan (Unknown route)
  • 16 Apr 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top